Shares of Humacyte Inc. (HUMA) are down over 70% from their 52-week high of $9.97, recorded last May, to trade around $2.
The company markets Symvess, a first-of-its-kind human-derived biologic vessel, designed for adults who need urgent surgery to restore blood flow to a damaged limb, especially when using the patient's own vein is not feasible. Approved by the FDA for treatment of extremity vascular trauma in December 2024, Symvess, an acellular tissue-engineered vessel, was commercially launched in the U.S. in late February 2025. Symvess generated $147 thousand in revenue related to the initial U.S. commercial launch in the first quarter of 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com